Adaptimmune reports early Phase I/II liposarcoma data for NY-ESO SPEAR T cells

Adaptimmune Therapeutics plc (NASDAQ:ADAP) said its NY-ESO SPEAR T cell therapy led to three partial responses and one case of stable disease in the first

Read the full 251 word article

User Sign In